Back to News
Market Impact: 0.25

DGRO ETF Factor Report

DGRONDAQ
Company FundamentalsCapital Returns (Dividends / Buybacks)Analyst InsightsHealthcare & BiotechBanking & Liquidity
DGRO       ETF Factor Report

Validea's fundamental report highlights the iShares Core Dividend Growth ETF (DGRO) as a Large-Cap Low Volatility fund with significant exposure to Quality (89) and Low Volatility (90) factors, alongside moderate Value (59) and low Momentum (38) scores. The ETF's portfolio is notably concentrated in the Financial sector and Biotechnology & Drugs industry. This factor profile positions DGRO as a compelling option for investors seeking stability and quality characteristics within their equity allocations.

Analysis

The iShares Core Dividend Growth ETF (DGRO) presents a distinct factor profile characterized by very high exposure to Quality (score of 89) and Low Volatility (score of 90), according to a Validea fundamental report. This suggests the fund's underlying holdings are predominantly stable, financially sound companies. In contrast, its Momentum score is low at 38, indicating the strategy does not chase recent market winners and is likely to lag in strongly trending markets. The ETF holds a moderate position on the value spectrum with a score of 59. As a Large-Cap Low Volatility ETF, its portfolio construction is consistent with these factor exposures. Notably, its largest sector concentration is in Financials, while its largest industry is Biotechnology & Drugs, providing specific insight into where the fund is sourcing these quality and low-volatility characteristics.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.15

Ticker Sentiment

DGRO0.00
NDAQ0.00

Key Decisions for Investors

  • Investors seeking a core equity holding with a defensive tilt should consider DGRO, as its high Quality and Low Volatility scores align with strategies focused on capital preservation and steady dividend growth.
  • Be aware that the ETF's low Momentum score of 38 suggests it may underperform market benchmarks during periods of strong, momentum-driven rallies.
  • Given the stated concentration in the Financial and Biotechnology & Drugs sectors, prospective buyers should assess their existing portfolio exposure to these areas to avoid unintended over-concentration.